Background
Phase III RCT enrolling 781 patients with previously untreated CD20+ CLL and clinically significant coexisting conditions (Cumulative Illness Rating Scale score >6 or estimated CrCl 30–69 mL/min), randomized 1:2:2 over six 28-day cycles.
Interventions and follow up
Arm A: Obinutuzumab + chlorambucil
Arm B: Rituximab + chlorambucil
Arm C: Chlorambucil monotherapy
Primary endpoint: Investigator-assessed PFS
mFollow up: ~23mo
Arm B: Rituximab + chlorambucil
Arm C: Chlorambucil monotherapy
Primary endpoint: Investigator-assessed PFS
mFollow up: ~23mo
Results
mPFS (A vs C): 26.7mo vs 11.1mo; HR 0.18, 95%CI 0.13–0.24; P<.001
mPFS (B vs C): 16.3mo vs 11.1mo; HR 0.44, 95%CI 0.34–0.57; P<.001
mPFS (A vs B): 26.7mo vs 15.2mo; HR 0.39, 95%CI 0.31–0.49; P<.001
Death rate (A vs C): 9% vs 20%; HR 0.41, 95%CI 0.23–0.74; P=.002
Death rate (B vs C): 15% vs 20%; HR 0.66, 95%CI 0.39–1.11; P=.11
Death rate (A vs B): 8% vs 12%; HR 0.66, 95%CI 0.41–1.06; P=.08
mPFS (B vs C): 16.3mo vs 11.1mo; HR 0.44, 95%CI 0.34–0.57; P<.001
mPFS (A vs B): 26.7mo vs 15.2mo; HR 0.39, 95%CI 0.31–0.49; P<.001
Death rate (A vs C): 9% vs 20%; HR 0.41, 95%CI 0.23–0.74; P=.002
Death rate (B vs C): 15% vs 20%; HR 0.66, 95%CI 0.39–1.11; P=.11
Death rate (A vs B): 8% vs 12%; HR 0.66, 95%CI 0.41–1.06; P=.08
Adverse events
Hematologic/cytopenias: Grade 3-4 neutropenia 33% vs 28% vs 16%, arm A vs B vs C
Infusion reactions/infections: Grade 3-4 infusion-related reactions 20% vs 4% vs 0%; grade 3-4 infections 14% vs 12% vs 14% (arm A vs B vs C); grade 3-4 events overall highest with obinutuzumab-chlorambucil, lowest with chlorambucil alone
Infusion reactions/infections: Grade 3-4 infusion-related reactions 20% vs 4% vs 0%; grade 3-4 infections 14% vs 12% vs 14% (arm A vs B vs C); grade 3-4 events overall highest with obinutuzumab-chlorambucil, lowest with chlorambucil alone
Conclusions
Adding an anti-CD20 antibody (obinutuzumab or rituximab) to chlorambucil improved PFS in untreated CLL with comorbidities; obinutuzumab-chlorambucil was superior to rituximab-chlorambucil in PFS and provided an overall survival advantage versus chlorambucil alone, with deeper, longer remissions.
Key Limitations
Chlorambucil backbone is now largely superseded by targeted agents; population restricted to comorbid/elderly patients; higher infusion-reaction burden with obinutuzumab; molecular high-risk subgroups underrepresented.
Clinical Context
Led to FDA/EMA approval of obinutuzumab for previously untreated CLL. ESMO/iwCLL guidelines now favor BTK inhibitors or venetoclax-based regimens over chemoimmunotherapy in most patients, but obinutuzumab is a key anti-CD20 partner in venetoclax-based fixed-duration therapy.
References